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Introduction
Painful vaso-occlusive episodes (VOEs) are the hallmark of sickle 
cell disease (SCD). These episodes of recurrent pain are caused by tissue 
ischemia, resulting from occlusion of the microcirculation by sickled 
red blood cells and are the most frequent complication of (SCD) [1]. 
Frequency and intensity of painful episodes are variable among patients 
with SCD. Some patients are rarely hospitalized for pain management, 
while others are often admitted for treatment with intravenous (IV) 
opioids. These frequently hospitalized patients may have pain that is 
refractory to conventional therapies for multifactorial reasons, and this 
can lead to sub-optimal pain control and frustration for both patients 
and clinicians [2,3]. 
 Traditional inpatient therapy for VOE includes IV hydration 
combined with administration of non-steroidal anti-inflammatory 
agents (NSAIDS) and IV opioids, often delivered via patient-
controlled analgesia (PCA) pump [4]. Additionally, supportive care 
and complementary and alternative therapies have been described 
as helpful adjuvants in the management of SCD patients with acute 
painful episodes [5-10]. For frequently hospitalized SCD patients with 
a recurrent severe pain phenotype, this combination is not always 
effective in achieving pain relief. It has been hypothesized that frequent 
exposure to opioids in these patients could lead to tolerance and, in 
extreme cases, opioid induced hyperalgesia (OIH), which are thought 
to contribute to opioid refractory pain [11-13]. Activation of the 
N-methyl-D-aspartate (NMDA) receptor has been implicated in opioid 
tolerance and OIH. Ketamine is an inhibiter of the NMDA receptor 
and has been shown to modulate opioid tolerance and OIH in both 
children and adults with perioperative and cancer-related pain [14-17]. 
While limited data is available, subanesthetic doses known as low-dose 
ketamine can be given as an IV bolus dose of less than 1 mg/kg or a 
continuous infusion at a rate of less than 1.2 mg/kg/h. At these doses 
ketamine does not appear to possess the sedative properties seen with 
higher anesthetic doses [18]. 
There is limited experience with the use of low-dose ketamine 
in SCD. Case series and case reports have documented improved 
analgesia, although some clinically significant side effects such as 
nystagmus, hypertension, dysphoria, and unresponsiveness were 
also noted. While most of these clinically significant side effects were 
associated with bolus dosing of ketamine, safety concerns remain 
with the use of low-dose ketamine in this population [19,20]. We here 
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Abstract
Background: Opioids are the mainstay of therapy for painful vasoocclusive episodes (VOEs) in sickle cell 
disease (SCD). Based on limited studies, low-dose ketamine could be a useful adjuvant analgesic for refractory SCD 
pain, but its safety and efficacy has not been evaluated in pediatric SCD. 
Procedure: Using retrospective chart review we recorded and compared characteristics of hospitalizations of 
33 children with SCD hospitalized with VOE who were treated with low-dose ketamine and opioid PCA vs. a paired 
hospitalization where the same patients received opioid PCA without ketamine. We seek to 1) describe a single 
center experience using adjuvant low-dose ketamine with opioid PCA for sickle cell related pain, 2) retrospectively 
explore the safety and efficacy of adjuvant low-dose ketamine for pain management, and 3) determine ketamine’s 
effect on opioid consumption in children and adolescents hospitalized with VOE.
Results: During hospitalizations where patients received ketamine, pain scores and opioid use were higher (6.48 
vs. 5.99; p=0.002 and 0.040 mg/kg/h vs. 0.032 mg/kg/h; p=0.004 respectively) compared to hospitalizations without 
ketamine. In 3 patients, ketamine was discontinued due to temporary and reversible psychotomimetic effects. There 
were no additional short term side effects of ketamine. 
Conclusions: Low-dose ketamine has an acceptable short-term safety profile for patients with SCD hospitalized 
for VOE. Lack of an opioid sparing effect of ketamine likely represents use of low-dose ketamine for patients 
presenting with more severe VOE pain. Prospective randomized studies of adjuvant low-dose ketamine for SCD 
pain are warranted to determine efficacy and long-term safety.
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present our experience with the use of adjuvant low-dose ketamine 
in children and adolescents with SCD hospitalized for painful VOE, 
and provide preliminary examination of its safety and efficacy in this 
population through a retrospective case-crossover study design. 
Materials and Methods
Research design and data sources
This study was approved by the Institutional Review Board of 
Children’s National Medical Center. Through retrospective chart 
review of pharmacy records, we identified patients with SCD who 
had received ketamine between September 1, 2010 and May 8, 2012. 
We then retrospectively selected and compared two painful VOE 
hospitalizations for each patient separated by a maximum of 24 
months. In one hospitalization the patient received adjuvant low-
dose ketamine infusion in addition to opioid PCA, at the discretion of 
the pain medicine physician. In the other hospitalization, the patient 
received opioid PCA alone, without adjuvant ketamine. All patients in 
both groups received standard care with NSAIDS, IV hydration, and 
supportive care interventions. 
Patients with SCD, 7-21 years old, with an admitting diagnosis 
of VOE, with or without an admission diagnosis of pneumonia or 
acute chest syndrome (ACS) were included. All demographics and 
hospitalization details, including pain and sedation scores every 4 hours 
and daily opioid administration (measured in morphine equivalents), 
were recorded through review of the electronic medical record (EMR). 
Pain scores that had been recorded using either the Numeric Rating 
Scale (NRS) or the Wong-Backer Faces Scale, and sedation scores 
that had been assessed utilizing The University of Michigan Sedation 
Scale (UMMS) were documented during the chart review [21,22]. 
Comorbidities such as history of asthma, priapism, kidney disease, or 
avascular necrosis, were also recorded from the EMR. 
Endpoints
Our primary endpoint to assess efficacy of adjuvant ketamine was 
daily opioid consumption during the hospitalizations. We compared 
the hospitalizations with and without adjuvant ketamine to determine a 
possible opioid-sparing effect of ketamine. To convert total daily opioid 
dose to IV morphine equivalents we used the following conversions: 
codeine to oral morphine (10:1), oxycodone: oral morphine (1:1.5), 
oral morphine: IV morphine (3:1), IV/oral hydromorphone: IV/oral 
morphine (5:1), tramadol: oral morphine (5:1), oral methadone: oral 
morphine, (1:4), oral methadone : intravenous methadone (2:1) [23,24]. 
Short term safety was assessed by recording when and if adjuvant low-
dose ketamine infusion was discontinued due to a suspected adverse 
event as documented in Pain Medicine progress notes. The sedative 
effect of adjuvant low-dose ketamine was assessed by noting recorded 
sedation scores. Secondary endpoints assessed through chart review 
included pain and sedation scores, administration of anti-emetics and 
antihistamines, and use of complementary and alternative therapies. Use 
of alternative pain management agents was defined as administration of 
gabapentin, pregabalin, duloxetine, fluoxetine, diazepam, or lorazepam 
and was also assessed through chart review. 
Data management and analysis
All study data was managed in REDCap electronic data capture 
tools hosted at Children’s National Medical Center [25]. The data 
was exported from REDCap to SAS 9.2 (SAS Institute, Cary, NC) 
for statistical analysis. We compared demographic and clinical 
characteristics of patient hospitalizations when they were treated 
with and without ketamine using univariate frequency distributions. 
Exploratory bivariate analyses (McNemar’s test and paired t-test for 
significant differences between paired samples) were used to compare 
variables between the paired hospitalizations. Multiple linear regressions 
was used with the continuous dependent variable of mean opioid use to 
attempt to control for key confounders including diagnosis of ACS, red 
blood cell transfusion, number of painful sites, pain score, and length 
of stay. 
Results
Thirty-three paired hospitalizations that occurred between October 
2008 and April 2012 met the study eligibility criteria. Demographic 
data reflective of the time of presentation for the PCA and ketamine 
hospitalization is presented in Table 1. The mean age of our patients 
was 15.6 years (range 7.5-21.4 years) and 67% were females. The mean 
duration until low-dose ketamine started was 1.17 days, with the 
majority of patients having low-dose ketamine added on hospital day 
2 or 3. The mean interval time between a patient’s 2 hospitalizations 
was 5.4 months (± 4.5 months, range=0.25 -19.3 months). We collected 
data on 242 paired inpatient days between the two hospitalizations. 
Twenty-six out of 33 patients (79%) had the PCA alone hospitalization 
before their PCA and ketamine hospitalization. Average number of 
hospitalizations in the 6 months prior to presentation for their PCA and 
adjuvant ketamine hospitalization was 2.1, and 21/33 patients (64%) 
had ≥ 2 hospitalizations in the 6 months prior. Low-dose ketamine 
was administered as a continuous infusion (0.1 mg/kg/h) for a mean 
duration of 3.11 days (± 2.29 days, range 0.8–11.91 days). In one patient, 
low-dose ketamine was temporarily escalated to a dose of 0.15 mg/kg/h. 
Three patients (9%) had their low-dose ketamine infusion 
discontinued or dose decreased due to a perception of an adverse effect 
Age
Mean (range) 15.6 years (7.5-21.4)
Gender
Female 22 (67%)
Phenotype
SS 23 (70%)
SBeta0  Thalassemia 1 (3%)
SC 8 (24%)
SBeta+Thalassemia 1 (3%)
Co-morbidities
Asthma or hx of severe ACS 23 (70%)
Avascular Necrosis 5 (15%)
Iron overload 3 (9%)
Kidney Disease/HTN 6 (18%)
Priapism 1 (3%)
Hydroxyurea therapy
Yes 12 (42%)
Average dose 22.74 mg/kg/day
Time to Ketamine start (± SD (range) 1.17 days (± 0.99)
(0.09-3.56)
PCA type Morphine 21 (64%)
Hydromorphone 12 (36%)
Day Ketamine Added HD 1 (n=6)
HD 2 (n=13)
HD 3 (n=7)
HD 4 (n=6)
HD 5 (n=1)
Total Duration of Ketamine (±SD) 3.11 days (± 2.29)
hx=history ACS=Acute Chest Syndrome, HTN=Hypertension, HD=hospital day 
Table 1: Demographic Characteristics of Ketamine+PCA group. n=33 patients.
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on the part of the patient, parent, or physician. The patient whose dose 
was increased to 0.15 mg/kg/h experienced vivid dreams, for which 
the infusion was decreased back to 0.1 mg/kg/h with resolution of 
the adverse effect. One patient had delusions after starting the low-
dose ketamine infusion. This effect was believed to be multifactorial 
and was managed by discontinuation of both the low-dose ketamine 
infusion and the continuous infusion of the opioid PCA, as well as 
administration of a red blood cell transfusion for severe anemia. The 
patient’s symptoms resolved after these interventions. The third patient 
had the low-dose ketamine infusion discontinued after 19.6 hours 
due to the patient’s complaint of feeling “dizzy” and the lack of effect 
perceived by the patient and family. There were no cardiac toxicities 
noted. Mean daily sedation score during the opioid PCA/low-dose 
ketamine hospitalization was 0.277 (range 0-1.8) vs. 0.173 (range 
0-1.6) in the opioid PCA hospitalization, p=0.078. Disease severity and 
hospitalization characteristics for each patient, and then by patient days 
are presented in Tables 2 and 3. Mean daily pain sores in the opioid 
PCA/low-dose ketamine hospitalization was higher at 6.48 vs. 5.99 in 
the opioid PCA alone hospitalization (p=0.002). More patients had 
concurrent ACS during the opioid PCA+ ketamine hospitalization 
vs. the opioid PCA alone hospitalization (42% vs. 15%, p=0.013). The 
use of supportive care and complementary therapies during the two 
hospitalizations are described in Figure 1. 
Mean opioid use during the opioid PCA/low-dose ketamine 
hospitalization and opioid PCA only hospitalization was 0.040 (± 
SD 0.011) and 0.032 (± SD 0.012) mg/kg/h morphine equivalents 
respectively (p=0.0038). Attempts were made to adjust for confounders 
impacting opioid use including, ACS, red blood cell transfusion, 
transfer to ICU, number of painful sites, and mean pain score through 
multiple linear regressions. There was no change in the mean opioid use 
after adjustment; therefore only crude opioid use is reported.
Discussion
We describe our experience with adjuvant low-dose ketamine 
therapy in children and adolescents with SCD and compare 
characteristics of hospitalizations with and without ketamine use. 
Ketamine was safe, in the short term, when given as continuous 
infusion of 0.1 mg/kg/h as an adjuvant to opioid PCA in children and 
adolescents with SCD hospitalized for VOE. Psychotomimetic effects 
were infrequent and were reversible with discontinuation of the infusion. 
While sedation scores were statistically different, average sedation score 
in both groups ranged from 0-1 (awake to mildly sedate) indicating no 
clinically significant differences in sedation between the two groups. As 
observed in other studies, although not statistically significant, a trend 
is seen with fewer anti-emetics used by patients receiving ketamine 
[26,27]. In comparison to prior studies, the lack of major adverse effects 
suggests that the delivery method and dose used in this study may have 
a more favorable side effect profile than bolus dosing for pediatric SCD 
patients. Prior case series describing five patients with SCD receiving 
low-dose ketamine reported one patient who experienced nystagmus, 
hypertension, and unresponsiveness after transition to a new infusion 
which was hypothesized to have caused an inadvertent bolus dose. 
Another patient in that same case series complained of dysphoria after 
the initial ketamine bolus and asked that drug is discontinued [19]. Due 
to our study design we are not able to comment on the long term effect 
of ketamine, more specifically neuroapoptosis, which has been recently 
raised as major concern and potentially results from the exposure of the 
developing brain to ketamine [28-30]. 
We did not observe an opioid sparing effect of low-dose ketamine 
in this group of frequently hospitalized patients. In fact, opioid 
requirement was higher during the admission when low-dose ketamine 
was prescribed. The reasons for this finding could be multifactorial in 
this retrospective study. Higher opioid use in the PCA and low-dose 
ketamine group could be due to a more severe painful crisis experienced 
by patients during their low-dose ketamine/opioid hospitalization. 
This is suggested by higher pain scores and increased number of 
painful sites during those hospitalizations. The presence of higher 
pain scores and increased opioid use in the low-dose ketamine/opioid 
PCA hospitalizations is in concert with our Pain Medicine group’s 
practice of adding ketamine for patients with more difficult to manage 
painful episodes. Furthermore, higher rates of ACS and need for red 
blood cell transfusion may also be indicators of a more severe painful 
crisis. Most patients had their adjuvant ketamine hospitalization at an 
older age which could also be suggestive of progression to more severe 
disease overtime. The increased number of painful sites noted during 
low-dose ketamine admissions could also reflect progression towards a 
PCA+ ketamine  PCA change p-value
Length of stay 
(days) (range)
5.6 
(2.5-13.7)
4.4 
(1.7-8.8)
 1.21  0.042°
Mean pain score on 
DOA
7.84 (3.5-10) 7.25 (3-10) 0.57  0.078°
Mean daily pain score 6.48 (0-10)  5.99 (0-10) 0.46 0.002°
Mean daily sedation 
score
0.277 (0-1.8) 0.173 (0-1.6)  0.12  0.078°
Duration of PCA (± SD) 4.37 days (± 2.5) 3.4 days (± 1.5) 22.5 hrs 0.050°
Concurrent ACS n (%) 14 (42%) 5 (15%)  0.013+
ICU transfer n (%) 3 (9%) 1 (3%)  0.317+
RBC transfusion n (%) 12 (36%) 7 (21%) 0.059+
DOA=day of admission, ACS=Acute Chest Syndrome, ICU=intensive care unit
°paired t-test,  +McNemars test
Table 2: Comparison of Hospitalization Characteristics n=33.
PCA+ ketamine  PCA p-value+
Days with pain score ≥ 8 146/235 (62%)  133/240 (55%) 0.113 
Number of painful sites ≥ 2=54% ≥ 2=45% 0.060
≥ 3=20% ≥ 3=7% 0.0001
Received Antiemetic 24/240 (10%) 33/241 (14%) 0.228
Received Antihistamine 79/240 (33%) 63/242 (26%) 0.060
+McNemars test
Table 3: Hospitalization characteristics and severity by patient days (n=242 patient 
days).
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Figure 1: Use of integrative therapies during hospitalizations.
alernative agents=administration of gabapentin, pregabalin, duloxetine, 
fluoxetine, diazepam, or lorazepam.
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chronic pain phenotype. The mean age of our patients was older than 
previously described cohorts of patients with SCD, which could suggest 
that older patients are more likely to exhibit evidence of a chronic pain 
phenotype and poor responsiveness to opioids leading physicians to 
seek additional therapies such as low-dose ketamine [31-33]. Our study 
population experienced much higher utilization of physical therapy 
services, whirlpool, and heat packs than previously reported [33]. 
Additionally, higher usage of neuropathic and other alternative pain 
management agents were recorded in a statistically significant number 
of patients during their ketamine hospitalization which may indicate 
the severe and refractory nature of their pain, which likely led to low-
dose ketamine administration. Patients with hemoglobin SC disease, 
generally considered to have milder disease, also received ketamine for 
pain demonstrating presence of this severe pain phenotype across the 
SCD genotypes. 
Our study population is also remarkable in that about two thirds of 
our patients had at least 3 hospitalizations in 6 months indicating that 
our sample represents a group of frequently hospitalized patients with 
severe disease. Prior studies have shown wide variability in the frequency 
of painful VOEs requiring hospitalization. About 5% of patients average 
3-10 hospitalizations per year for painful crisis, accounting for 33% of 
episodes treated by physicians [3]. Our study group also likely reflects 
the poorly compliant adolescent patients, since only 36% of our study 
patients were receiving hydroxyurea at the time of hospital admission, 
although given the combination of frequent hospitalizations and high 
rates of ACS these patients are likely prime candidates for hydroxyruea 
therapy [34]. 
We conclude that for difficult to control pain in children and 
adolescents with SCD hospitalized for VOE, low-dose ketamine 
infusion has an acceptable short-term safety profile and may be used an 
adjuvant to opioids. We were unable to detect an opioid sparing effect of 
ketamine in our population which is likely attributable, at least in part, 
to the increased severity and chronicity of pain in the PCA plus low-
dose ketamine hospitalizations. We cannot comment on the efficacy 
of the regimen due to selection bias introduced by our retrospective 
non-randomized case-control design, where adjuvant ketamine was 
prescribed at the discretion of the treating physician. Additionally, 
with a relatively small sample size we were unable to control for disease 
severity, pain scores, opioid use, and SCD-related complications, 
and pharmacogenetic variations which further impairs our ability 
to comment on the efficacy of adjuvant ketamine. Further studies, 
including a large prospective randomized control trial that could 
address the above mentioned challenges, are necessary to determine the 
safety and efficacy of adjuvant ketamine to opioid PCA for patients with 
SCD. Efficacy studies should also include long-term safety assessment. 
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